Xinnate AB
🇸🇪Sweden
A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, STEP-study
Phase 2
Not yet recruiting
- Conditions
- Epidermolysis Bullosa (EB)
- Interventions
- Drug: Vehicle (placebo)
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Xinnate AB
- Target Recruit Count
- 26
- Registration Number
- NCT06594393
- Locations
- 🇸🇪
University hospital, Lund, Skane, Sweden
Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.
Phase 1
Completed
- Conditions
- BlisterWound of SkinEpidermolysis BullosaVaricose Ulcer of Lower Limb
- Interventions
- Drug: TCP-25 gel 2.9 mg/ml or placebo gelDrug: TCP-25 gel 0.86 mg/ml or placebo gelDrug: TCP-25 gel 8.6 mg/ml or placebo gel
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Xinnate AB
- Target Recruit Count
- 35
- Registration Number
- NCT05378997
- Locations
- 🇸🇪
Skåne University Hospital in Lund, Clinical Trial Unit, Lund, Sweden
© Copyright 2025. All Rights Reserved by MedPath